Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2020 | Non-adherence to tamoxifen in CANTO cohort over 3 years

Barbara Pistilli, MD, Institut Gustave Roussy, Villejuif, France, discusses non-adherence to endocrine therapy when treating breast cancer. Using the prospective multicenter CANTO cohort, non-adherence to tamoxifen was assessed in premenopausal women 3 years after prescription. After the first year non-adherence was 1 in 6 but sharply increased to 1 in 3 by the third year. Dr Pistilli emphasises the need for an intervention programme to reduce non-adherence. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.